Drug Approval | May 30, 2026
Lupin secures FDA nod for generic Sutab tablets with 180-day exclusivity
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
As per National Health Accounts (NHA) estimates, government health expenditure rose steadily between 2013-14 and 2022-23, while out-of-pocket spending declined significantly
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Subscribe To Our Newsletter & Stay Updated
